The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511).
Taofeek Kunle Owonikoko
No relevant relationships to disclose
Suzanne Eleanor Dahlberg
No relevant relationships to disclose
Saad A. Khan
No relevant relationships to disclose
David E. Gerber
No relevant relationships to disclose
Jonathan Dowell
No relevant relationships to disclose
Rebecca Anne Moss
No relevant relationships to disclose
Chandra Prakash Belani
No relevant relationships to disclose
Christine L. Hann
No relevant relationships to disclose
Charu Aggarwal
No relevant relationships to disclose
Suresh S. Ramalingam
No relevant relationships to disclose